Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone
Authors:
- Aleksandar KrunicAKAleksandar Krunic
- Ana CiureaACAna Ciurea
- Andrew SchemanASAndrew Scheman
- 1 January 2008
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 58 (1) , 60-62
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Have Oral Contraceptives Reduced the Prevalence of Acne? A Population-Based Study of Acne vulgaris, Tobacco Smoking and Oral ContraceptivesDermatology, 2002
- AcneAmerican Journal of Clinical Dermatology, 2002
- Low-dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patientsJournal of the American Academy of Dermatology, 2000
- Inhibition of skin 5α-reductase by oral contraceptive progestinsin vitroGynecological Endocrinology, 2000
- Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgarisJournal of the American Academy of Dermatology, 1997
- Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trialObstetrics & Gynecology, 1997
- Tolerance of spironolactoneBritish Journal of Dermatology, 1988
- Oral spironolactone: an effective treatment for acne vulgaris in womenBritish Journal of Dermatology, 1986
- Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopeciaBritish Journal of Dermatology, 1985
- Oral spironolactone improves acne vulgaris and reduces sebum excretionBritish Journal of Dermatology, 1984